Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Inclusion Criteria: * PRE-REGISTRATION INCLUSION (STEP 0) * Patient must have undergone a radical prostatectomy (RP) and must be registered to step 0 of this study at least 6 weeks after but not more than 16 weeks after their radical prostatectomy * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 * Patient with a prior or concurrent malignancy within 5 years of registration, whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * For patients with no previous Decipher score: Tumor tissue specimen from prostatectomy must be available and ready to be shipped * INCLUSION CRITERIA FOR RANDOMIZATION (STEP 1) * For patients who have previously had Decipher score performed by Decipher Biosciences, they must have score of \>= 0.6 * For patients who did not have a Decipher score previously perfo…